152 related articles for article (PubMed ID: 35676330)
1. Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification.
Yu Y; Lajkosz K; Finelli A; Fleshner N; van der Kwast TH; Downes MR
Mod Pathol; 2022 Nov; 35(11):1695-1701. PubMed ID: 35676330
[TBL] [Abstract][Full Text] [Related]
2. Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.
Downes MR; Liu KN; Yu Y; Lajkosz K; Kroon LJ; Hollemans E; Fleshner N; Finelli A; van Leenders GJLH; Iczkowski KA; van der Kwast TH
Clin Genitourin Cancer; 2024 Feb; 22(1):47-55. PubMed ID: 37558528
[TBL] [Abstract][Full Text] [Related]
3. Addition of cribriform pattern 4 and intraductal prostatic carcinoma into the CAPRA-S tool improves post-radical prostatectomy patient stratification in a multi-institutional cohort.
Nguyen NJ; Liu K; Lajkosz K; Iczkowski KA; van der Kwast TH; Downes MR
J Clin Pathol; 2024 Feb; ():. PubMed ID: 38378247
[TBL] [Abstract][Full Text] [Related]
4. Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.
Jeyapala R; Kamdar S; Olkhov-Mitsel E; Zlotta A; Fleshner N; Visakorpi T; van der Kwast T; Bapat B
Clin Genitourin Cancer; 2022 Jun; 20(3):e217-e226. PubMed ID: 35151601
[TBL] [Abstract][Full Text] [Related]
5. Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy.
Downes MR; Xu B; van der Kwast TH
Eur J Cancer; 2021 May; 148():432-439. PubMed ID: 33077335
[TBL] [Abstract][Full Text] [Related]
6. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
Diamand R; Peltier A; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; Nguyen TA; Fournier G; Fiard G; Ploussard G; Roumeguère T; Albisinni S
Prostate; 2023 May; 83(6):572-579. PubMed ID: 36705314
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
Budäus L; Isbarn H; Tennstedt P; Salomon G; Schlomm T; Steuber T; Haese A; Chun F; Fisch M; Michl U; Heinzer H; Huland H; Graefen M
BJU Int; 2012 Dec; 110(11):1714-20. PubMed ID: 22520619
[TBL] [Abstract][Full Text] [Related]
11. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients.
Xu H; Zhu Y; Dai B; Ye DW
Asian J Androl; 2018; 20(6):551-554. PubMed ID: 30027928
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
[TBL] [Abstract][Full Text] [Related]
13. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
14. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
15. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients.
Yoshida T; Nakayama M; Takeda K; Arai Y; Kakimoto K; Nishimura K
Urol Int; 2012; 89(1):45-51. PubMed ID: 22441013
[TBL] [Abstract][Full Text] [Related]
16. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
Mazzone E; Gandaglia G; Ploussard G; Marra G; Valerio M; Campi R; Mari A; Minervini A; Serni S; Moschini M; Marquis A; Beauval JB; van den Bergh R; Rahota RG; Soeterik T; Roumiguiè M; Afferi L; Zhuang J; Guo H; Mattei A; Gontero P; Cucchiara V; Stabile A; Fossati N; Montorsi F; Briganti A
Eur Urol; 2022 Feb; 81(2):193-203. PubMed ID: 34399996
[TBL] [Abstract][Full Text] [Related]
17. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
Ishizaki F; Hoque MA; Nishiyama T; Kawasaki T; Kasahara T; Hara N; Takizawa I; Saito T; Kitamura Y; Akazawa K; Takahashi K
Jpn J Clin Oncol; 2011 Nov; 41(11):1259-64. PubMed ID: 21940731
[TBL] [Abstract][Full Text] [Related]
18. Associations Between Intraductal Prostate Cancer and Metastases Following Radical Prostatectomy in Men With Prostate Cancer in the Veterans Affairs Database.
Nelson TJ; Kumar A; Nalawade V; Nonato T; Shabaik A; Roma A; Rose BS; McKay RR
Clin Genitourin Cancer; 2023 Aug; 21(4):452-458. PubMed ID: 37095044
[TBL] [Abstract][Full Text] [Related]
19. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
[TBL] [Abstract][Full Text] [Related]
20. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
